Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 11, November, p. 1593–1600

doi: 10.17219/acem/75511

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Significance of mutations in the region coding for NS3/4 protease in patients infected with HCV genotype 1b

Tadeusz W. Łapiński1,A,B,C,D,E,F, Magdalena Rogalska-Płońska1,B,F, Oksana Kowalczuk2,B,C, Joanna Kiśluk2,B,C, Joanna Zurnowska2,B,C, Jacek Nikliński2,F, Robert Flisiak1,F

1 Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Poland

2 Department of Clinical Molecular Biology, Medical University of Bialystok, Poland

Abstract

Background. Fast hepatitis C virus (HCV) replication is one of the reasons for frequent changes in viral genome.
Objectives. The objective of this study was to evaluate the frequency and type of mutation in NS3/4 protease in patients with HCV genotype 1b and to determine the effect of the mutation on viral load, fibrosis stage, alanine aminotransferase (ALT) activity, and alpha-fetoprotein (AFP) level.
Material and Methods. The study included 46 treatment-naïve patients, infected with HCV genotype 1b. Mutations were analyzed after isolating HCV RNA, and then evaluating the compliance of the amino acid sequence, using 3500 Genetic Analyzer (Applied Biosystems, Foster City, USA). RNA fragment from nucleotide 1–181 encoding NS3/4 protease was subjected to analysis.
Results. Mutations were demonstrated in 65% of subjects. Changes in the protease region affecting resistance to treatment (T54, Q80, V158, M175, D186) were detected in 10.8% of patients. Substitution mutation at T72 was found most frequently – in 49.9% of cases. In 13% of patients, mutation at G86 was demonstrated, including G86P in 5 patients and G86S in 1 patient. In the group of patients with T72 mutation, viral load was significantly higher (1.3 × 106 IU/mL vs 1.0 × 105 IU/mL; p = 0.01), AFP level was higher and fibrosis level was lower (1.26 vs 2.17; p = 0.008) compared to the patients without the mutation. Cryoglobulinemia was observed in 74% of patients with mutation at position T72.
Conclusion. Natural mutations of the region coding for NS3/4 protease are found frequently in patients infected with genotype 1b, but they may cause resistance to antiviral agents only in 11% of patients. Changes were most frequently found at position T72. Mutations at position T72 are correlated with the cryoglobulinemia occurrence. This is a substitution mutation, accompanied by a high viral load, high ALT activity and AFP level, which may point to a more unfavorable influence of such a modified virus, compared to wild-type virus, onto pathological processes in the liver.

Key words

mutations, cryoglobulinemia, hepatitis C virus genotype 1b, NS3/4 protease

References (24)

  1. Domingo E, Sheldon J, Perales C. Viral quasispecies evolution. Microbiol Mol Biol Rev. 2012;76:159–216.
  2. Gao Y, Yu X, Xue B, et al. Inhibition of hepatitis C virus infection by DNA aptamer against NS2 protein. PLoS ONE. 2014;9:e90333.
  3. Izumi N, Hayashi N, Kumada H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014;49:941–953.
  4. Lenz O, de Bruijne J, Vijgen L, et al. Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy. Gastroenterology. 2012;143: 1176–1178.
  5. Phenotype Working Group, Drug Development Advisory Group. Clinically relevant HCV drug resistance mutations figure and tables (updated). Ann Forum Collab HIV Res. 2015;14:1–8.
  6. Pilot-Matias T, Tripathi R, Cohen D, et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother. 2015;59: 988–997.
  7. Apelian D. Achillion Pharmaceuticals. http://www.informedhorizons.com/hepdart2013. Accessed on December 19, 2013.
  8. Lim SR, Qin X, Susser S, et al. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrob Agents Chemother. 2012;56:271–279.
  9. Ali A, Aydin C, Gildemeister R, et al. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem Biol. 2013;8:1469–1478.
  10. Ahmad J, Eng FJ, Branch AD. HCV and HCC: Clinical update and a review of HCC-associated viral mutations in the core gene. Semin Liver Dis. 2011;31:347–355.
  11. Paolucci S, Fiorina L, Piralla A, et al. Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients. J Virol. 2012; 9:245.
  12. Jaspe RC, Sulbarán YF, Sulbarán MZ, Loureiro CL, Rangel HR, Pujol FH. Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates. J Virol. 2012;9:214.
  13. Miura M, Maekawa S, Takano S, et al. Deep-sequencing analysis of the association between the quasispecies nature of the hepatitis C virus core region and disease progression. J Virol. 2013;87:12541–12551.
  14. Sølund C, Krarup H, Ramirez S; DANHEP group. Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: Identification of viral resistance mutations. PLoS ONE. 2014;9:e113034.
  15. Ferraro D, Urone N, Di Marco V, Craxì A. HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors. Infect Genet Evol. 2014;23:80–85.
  16. Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. World J Gastroenterol. 2013;19:8940–8948.
  17. De Meyer S, Ghys A, Foster GR, et al. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. J Viral Hepat. 2013;20:395–403.
  18. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene. 2010;29: 2309–2324.
  19. Poon A, Chao L. The rate of compensatory mutation in the DNA bacteriophage phiX174. Genetics. 2005;170:989–999.
  20. Lee MH, Yang HI, Lu SN; REVEAL-HCV Study Group. Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. Int J Cancer. 2014;135:1119-1126.
  21. Hu Z, Muroyama R, Kowatari N, Chang J, Omata M, Kato N. Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma. Cancer Sci. 2009;100:2465–2468.
  22. Vallet S, Gouriou S, Nkontchou G, et al. Is hepatitis C virus NS3 protease quasispecies heterogeneity predictive of progression from cirrhosis to hepatocellular carcinoma? J Viral Hepat. 2007;14:96–106.
  23. Yoshimi S, Ochi H, Murakami E, et al. Rapid, sensitive, and accurate evaluation of drug resistant mutant (NS5A-Y93H) strain frequency in genotype 1b HCV by invader assay. PLoS ONE. 2015;10:e0130022.
  24. Verga-Gérard A, Porcherot M, Meyniel-Schicklin L, André P, Lotteau V, Perrin-Cocon L. Hepatitis C virus/human interactome identifies SMURF2 and the viral protease as critical elements for the control of TGF-β signa ling. FASEB J. 2013;27:4027–4040.
© Wroclaw Medical University